Utility of nuclear matrix protein (NMP22) in the detection of recurrent bladder cancer.
This article examines the Nuclear Matrix Protein (NMP22) urine test for recurrent bladder cancer detection. Studies with NMP22 are compared to cytology for sensitivity and specificity. False positives and false negatives do occur, and consequences of these are discussed. Speculations are made regarding possible future uses of this test.
Grocela
J A
JA
Department of Urology, Harvard Medical School, Boston, Massachusetts, USA.
McDougal
W S
WS
D014408:Biomarkers, Tumor / Q000378:metabolism*; D006801:Humans; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D009687:Nuclear Proteins / Q000378:metabolism*; D012680:Sensitivity and Specificity; D001749:Urinary Bladder Neoplasms / Q000378:metabolism* / Q000473:pathology; D014571:Urologic Neoplasms / Q000378:metabolism
D014408:Biomarkers, Tumor; D009687:Nuclear Proteins; C100379:nuclear matrix protein 22